Document Detail

Polyquad-preserved travoprost/timolol, benzalkonium chloride (BAK)-preserved travoprost/timolol, and latanoprost/timolol in fixed combinations: a rabbit ocular surface study.
MedLine Citation:
PMID:  21424577     Owner:  NLM     Status:  Publisher    
INTRODUCTION: The aim of this study was to use a validated acute rabbit model to test the toxicity of a novel formulation of fixed-combination travoprost 0.004%/timolol 0.5% ophthalmic solution, which contains the antimicrobial preservative polyquaternium-1 (PQ), compared with the commercial formulation of fixed combinations travoprost 0.004%/timolol 0.5% ophthalmic solution and latanoprost 0.005%/timolol 0.5% ophthalmic solution, which both contain the preservative benzalkonium chloride (BAK). METHODS: Adult male New Zealand albino rabbits (n=24) were randomly divided into four groups. Phosphatebuffered saline (PBS), travoprost/timolol PQ, travoprost/timolol BAK, or latanoprost/timolol BAK were instilled onto rabbit eyes one drop, 15 times at 5 minute intervals. The ocular surface reactions were investigated at hour 4 and day 1 using slit lamp examination; in-vivo confocal microscopy (IVCM) for cornea, limbus, and conjunctiva-associated lymphoid tissue (CALT); conjunctival impression cytology; and standard immunohistology in cryosections for detecting CD45+ infiltrating cells and MUC-5AC-labeled cells. RESULTS: Travoprost/timolol PQ was better tolerated than travoprost/timolol BAK or latanoprost/timolol BAK. This improved tolerance was evident via clinical observation under slit lamp, IVCM in different layers of the cornea and conjunctiva, conjunctival impression cytology of superficial epithelium aspects, and immunohistochemistry for inflammatory infiltration of CD45+ cells in the cornea and goblet cell distribution. Travoprost/timolol PQ was similar to PBS in regards to in-vivo findings, the Draize test for ocular irritation, and epithelial and limbal aspects as evaluated with IVCM. Treatment with either travoprost/timolol PQ or PBS produced no obvious inflammatory infiltration inside and outside the CALT follicles, yielded similar IVCM toxicity scores and CD45+ cell counts, and eyes treated with either solution had normal goblet cells. CONCLUSION: The fixed combination of travoprost/timolol with 0.001% PQ had decreased ocular surface toxicity relative to the BAK-containing solutions. The potential benefit to the human ocular surface with oncedaily dosing needs to be evaluated clinically.
Hong Liang; Françoise Brignole-Baudouin; Aude Pauly; Luisa Riancho; Christophe Baudouin
Related Documents :
17765677 - Estrogen-related receptor beta/nr3b2 controls epithelial cell fate and endolymph produc...
17167097 - Progressive deafness and altered cochlear innervation in knock-out mice lacking prosapo...
15890317 - Endothelial nitric oxide synthase upregulation in the guinea pig organ of corti after a...
2901187 - Modulation of cellular transglutaminase: protease-induced activation.
18708057 - Holfml1, a novel secreted glycoprotein, enhances the proliferation of human cancer cell...
8373417 - Antisense and sense cdna expression cloning using autonomously replicating vectors and ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-3-17
Journal Detail:
Title:  Advances in therapy     Volume:  -     ISSN:  1865-8652     ISO Abbreviation:  -     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-3-22     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8611864     Medline TA:  Adv Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
INSERM, UMR_S968, Paris, F-75012, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A proteomics study reveals a predominant change in MaoB expression in platelets of healthy volunteer...
Next Document:  5D (13)C-detected experiments for backbone assignment of unstructured proteins with a very low signa...